1 | plus | 24,195 |
2 | indanyl | 20 |
3 | 62304 | 5 |
4 | alone.one | 4 |
5 | mofetil-based | 4 |
6 | -α. | 3 |
7 | enwrapping | 3 |
8 | group.for | 3 |
9 | 'off'/dbs | 2 |
10 | 'on'/dbs | 2 |
11 | +biweekly | 2 |
12 | -infusion | 2 |
13 | 1.5mg/m2 | 2 |
14 | 13727 | 2 |
15 | 1mg/m | 2 |
16 | alfa-2b/ | 2 |
17 | alone/plus | 2 |
18 | availability-lowering | 2 |
19 | avancée | 2 |
20 | besylate/atorvastatin | 2 |
21 | cmf→ | 2 |
22 | dm+ | 2 |
23 | fibrillation-triggered | 2 |
24 | i-rituximab | 2 |
25 | inhibitor/ | 2 |
26 | pdt/sham | 2 |
27 | post-systemic | 2 |
28 | trihydrate-potassium | 2 |
29 | versus/or | 2 |
30 | +single-dose | 1 |
31 | +tcm | 1 |
32 | -competency-based | 1 |
33 | -l-histidinato | 1 |
34 | -plasma | 1 |
35 | .low-dose | 1 |
36 | /16α-oh | 1 |
37 | /infusional | 1 |
38 | /lamivudine/ | 1 |
39 | 0-baseline- | 1 |
40 | 0.50-mg | 1 |
41 | 10328 | 1 |
42 | 120/harmony | 1 |
43 | 3,4-pyrrolate | 1 |
44 | 300,000-iu | 1 |
45 | 300mg/100ml | 1 |
46 | 4'-0-tetrahydropyranyl | 1 |
47 | 5-grass-pollen | 1 |
48 | 5-nitro-2-3-phenylpropylamino | 1 |
49 | acetateplus | 1 |
50 | alone-were | 1 |
51 | ano-mucosal | 1 |
52 | antibovine | 1 |
53 | at-anti-cd45 | 1 |
54 | at-b10-30f11 | 1 |
55 | base-stabilized | 1 |
56 | besylate/ | 1 |
57 | bild | 1 |
58 | clinician-provided | 1 |
59 | contramid | 1 |
60 | darunavir/ | 1 |
61 | desaturates | 1 |
62 | dipivoxil-resistant | 1 |
63 | doxycycline/active | 1 |
64 | ethylenediaminetetramethylene | 1 |
65 | exhibites | 1 |
66 | ezetimibe+phytosterol | 1 |
67 | formulations-the | 1 |
68 | gamma-1b.the | 1 |
69 | gimbaled | 1 |
70 | glotte | 1 |
71 | group-received | 1 |
72 | group=59.10+/-12.18 | 1 |
73 | i-anti-cd20 | 1 |
74 | imipenem/0.5g | 1 |
75 | improving/modifying | 1 |
76 | injection+mifepristone+traditional | 1 |
77 | intermedian-dose | 1 |
78 | interno | 1 |
79 | jinlianqingre | 1 |
80 | kg−1 | 1 |
81 | mbl-mediated | 1 |
82 | mol/liter | 1 |
83 | monotherapy-based | 1 |
84 | morepa | 1 |
85 | n2-labeled | 1 |
86 | nevirapine+/- | 1 |
87 | orodispersable | 1 |
88 | phase.following | 1 |
89 | pheral-action | 1 |
90 | pirarubicin/ | 1 |
91 | plub | 1 |
92 | polyglutamated | 1 |
93 | post-generic | 1 |
94 | probe/mirna | 1 |
95 | prolonging/maintaining | 1 |
96 | propionate/ | 1 |
97 | qd-based | 1 |
98 | rt+oral | 1 |
99 | sodium/sulbactam | 1 |
100 | sulfate-topical | 1 |
101 | sulphomethate | 1 |
102 | supra-bioavailable | 1 |
103 | training-shared | 1 |
104 | unheated/heated | 1 |
105 | use/no | 1 |
106 | vesrus | 1 |
107 | xinafoate/ | 1 |
108 | z-val-ala-asp-fluoromethylketone | 1 |
109 | zr-labeled | 1 |
1 | 'off'/dbs | 2 |
2 | 'on'/dbs | 2 |
3 | +biweekly | 2 |
4 | +single-dose | 1 |
5 | +tcm | 1 |
6 | -competency-based | 1 |
7 | -infusion | 2 |
8 | -l-histidinato | 1 |
9 | -plasma | 1 |
10 | -α. | 3 |
11 | .low-dose | 1 |
12 | /16α-oh | 1 |
13 | /infusional | 1 |
14 | /lamivudine/ | 1 |
15 | 0-baseline- | 1 |
16 | 0.50-mg | 1 |
17 | 1.5mg/m2 | 2 |
18 | 10328 | 1 |
19 | 120/harmony | 1 |
20 | 13727 | 2 |
21 | 1mg/m | 2 |
22 | 3,4-pyrrolate | 1 |
23 | 300,000-iu | 1 |
24 | 300mg/100ml | 1 |
25 | 4'-0-tetrahydropyranyl | 1 |
26 | 5-grass-pollen | 1 |
27 | 5-nitro-2-3-phenylpropylamino | 1 |
28 | 62304 | 5 |
29 | acetateplus | 1 |
30 | alfa-2b/ | 2 |
31 | alone-were | 1 |
32 | alone.one | 4 |
33 | alone/plus | 2 |
34 | ano-mucosal | 1 |
35 | antibovine | 1 |
36 | at-anti-cd45 | 1 |
37 | at-b10-30f11 | 1 |
38 | availability-lowering | 2 |
39 | avancée | 2 |
40 | base-stabilized | 1 |
41 | besylate/ | 1 |
42 | besylate/atorvastatin | 2 |
43 | bild | 1 |
44 | clinician-provided | 1 |
45 | cmf→ | 2 |
46 | contramid | 1 |
47 | darunavir/ | 1 |
48 | desaturates | 1 |
49 | dipivoxil-resistant | 1 |
50 | dm+ | 2 |
51 | doxycycline/active | 1 |
52 | enwrapping | 3 |
53 | ethylenediaminetetramethylene | 1 |
54 | exhibites | 1 |
55 | ezetimibe+phytosterol | 1 |
56 | fibrillation-triggered | 2 |
57 | formulations-the | 1 |
58 | gamma-1b.the | 1 |
59 | gimbaled | 1 |
60 | glotte | 1 |
61 | group-received | 1 |
62 | group.for | 3 |
63 | group=59.10+/-12.18 | 1 |
64 | i-anti-cd20 | 1 |
65 | i-rituximab | 2 |
66 | imipenem/0.5g | 1 |
67 | improving/modifying | 1 |
68 | indanyl | 20 |
69 | inhibitor/ | 2 |
70 | injection+mifepristone+traditional | 1 |
71 | intermedian-dose | 1 |
72 | interno | 1 |
73 | jinlianqingre | 1 |
74 | kg−1 | 1 |
75 | mbl-mediated | 1 |
76 | mofetil-based | 4 |
77 | mol/liter | 1 |
78 | monotherapy-based | 1 |
79 | morepa | 1 |
80 | n2-labeled | 1 |
81 | nevirapine+/- | 1 |
82 | orodispersable | 1 |
83 | pdt/sham | 2 |
84 | phase.following | 1 |
85 | pheral-action | 1 |
86 | pirarubicin/ | 1 |
87 | plub | 1 |
88 | plus | 24,195 |
89 | polyglutamated | 1 |
90 | post-generic | 1 |
91 | post-systemic | 2 |
92 | probe/mirna | 1 |
93 | prolonging/maintaining | 1 |
94 | propionate/ | 1 |
95 | qd-based | 1 |
96 | rt+oral | 1 |
97 | sodium/sulbactam | 1 |
98 | sulfate-topical | 1 |
99 | sulphomethate | 1 |
100 | supra-bioavailable | 1 |
101 | training-shared | 1 |
102 | trihydrate-potassium | 2 |
103 | unheated/heated | 1 |
104 | use/no | 1 |
105 | versus/or | 2 |
106 | vesrus | 1 |
107 | xinafoate/ | 1 |
108 | z-val-ala-asp-fluoromethylketone | 1 |
109 | zr-labeled | 1 |
1 | dm+ | 2 |
2 | nevirapine+/- | 1 |
3 | 0-baseline- | 1 |
4 | -α. | 3 |
5 | alfa-2b/ | 2 |
6 | /lamivudine/ | 1 |
7 | besylate/ | 1 |
8 | propionate/ | 1 |
9 | xinafoate/ | 1 |
10 | pirarubicin/ | 1 |
11 | darunavir/ | 1 |
12 | inhibitor/ | 2 |
13 | i-anti-cd20 | 1 |
14 | at-b10-30f11 | 1 |
15 | kg−1 | 1 |
16 | 1.5mg/m2 | 2 |
17 | 62304 | 5 |
18 | at-anti-cd45 | 1 |
19 | 13727 | 2 |
20 | group=59.10+/-12.18 | 1 |
21 | 10328 | 1 |
22 | -plasma | 1 |
23 | probe/mirna | 1 |
24 | morepa | 1 |
25 | i-rituximab | 2 |
26 | plub | 1 |
27 | post-systemic | 2 |
28 | post-generic | 1 |
29 | clinician-provided | 1 |
30 | gimbaled | 1 |
31 | n2-labeled | 1 |
32 | zr-labeled | 1 |
33 | training-shared | 1 |
34 | fibrillation-triggered | 2 |
35 | qd-based | 1 |
36 | mofetil-based | 4 |
37 | -competency-based | 1 |
38 | monotherapy-based | 1 |
39 | unheated/heated | 1 |
40 | mbl-mediated | 1 |
41 | polyglutamated | 1 |
42 | group-received | 1 |
43 | base-stabilized | 1 |
44 | contramid | 1 |
45 | bild | 1 |
46 | formulations-the | 1 |
47 | gamma-1b.the | 1 |
48 | supra-bioavailable | 1 |
49 | orodispersable | 1 |
50 | ethylenediaminetetramethylene | 1 |
51 | antibovine | 1 |
52 | alone.one | 4 |
53 | z-val-ala-asp-fluoromethylketone | 1 |
54 | alone-were | 1 |
55 | jinlianqingre | 1 |
56 | +single-dose | 1 |
57 | intermedian-dose | 1 |
58 | .low-dose | 1 |
59 | sulphomethate | 1 |
60 | 3,4-pyrrolate | 1 |
61 | glotte | 1 |
62 | doxycycline/active | 1 |
63 | avancée | 2 |
64 | imipenem/0.5g | 1 |
65 | 0.50-mg | 1 |
66 | prolonging/maintaining | 1 |
67 | enwrapping | 3 |
68 | availability-lowering | 2 |
69 | phase.following | 1 |
70 | improving/modifying | 1 |
71 | /16α-oh | 1 |
72 | sulfate-topical | 1 |
73 | /infusional | 1 |
74 | injection+mifepristone+traditional | 1 |
75 | rt+oral | 1 |
76 | ano-mucosal | 1 |
77 | 300mg/100ml | 1 |
78 | ezetimibe+phytosterol | 1 |
79 | indanyl | 20 |
80 | 4'-0-tetrahydropyranyl | 1 |
81 | 1mg/m | 2 |
82 | pdt/sham | 2 |
83 | sodium/sulbactam | 1 |
84 | +tcm | 1 |
85 | trihydrate-potassium | 2 |
86 | 5-grass-pollen | 1 |
87 | besylate/atorvastatin | 2 |
88 | -infusion | 2 |
89 | pheral-action | 1 |
90 | use/no | 1 |
91 | 5-nitro-2-3-phenylpropylamino | 1 |
92 | interno | 1 |
93 | -l-histidinato | 1 |
94 | mol/liter | 1 |
95 | versus/or | 2 |
96 | group.for | 3 |
97 | 'off'/dbs | 2 |
98 | 'on'/dbs | 2 |
99 | desaturates | 1 |
100 | exhibites | 1 |
101 | plus | 24,195 |
102 | alone/plus | 2 |
103 | acetateplus | 1 |
104 | vesrus | 1 |
105 | dipivoxil-resistant | 1 |
106 | 300,000-iu | 1 |
107 | +biweekly | 2 |
108 | 120/harmony | 1 |
109 | cmf→ | 2 |